|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCAF17 |
Gene summary for DCAF17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCAF17 | Gene ID | 80067 |
| Gene name | DDB1 and CUL4 associated factor 17 | |
| Gene Alias | C20orf37 | |
| Cytomap | 2q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | F5H7W1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80067 | DCAF17 | LZE4T | Human | Esophagus | ESCC | 1.20e-04 | 1.45e-01 | 0.0811 |
| 80067 | DCAF17 | LZE7T | Human | Esophagus | ESCC | 1.02e-03 | 2.14e-01 | 0.0667 |
| 80067 | DCAF17 | LZE24T | Human | Esophagus | ESCC | 2.65e-05 | 1.39e-01 | 0.0596 |
| 80067 | DCAF17 | P2T-E | Human | Esophagus | ESCC | 4.78e-11 | 1.37e-01 | 0.1177 |
| 80067 | DCAF17 | P4T-E | Human | Esophagus | ESCC | 8.33e-13 | 2.86e-01 | 0.1323 |
| 80067 | DCAF17 | P5T-E | Human | Esophagus | ESCC | 4.62e-10 | 1.45e-01 | 0.1327 |
| 80067 | DCAF17 | P8T-E | Human | Esophagus | ESCC | 4.16e-08 | 8.87e-02 | 0.0889 |
| 80067 | DCAF17 | P9T-E | Human | Esophagus | ESCC | 3.05e-07 | 1.72e-01 | 0.1131 |
| 80067 | DCAF17 | P10T-E | Human | Esophagus | ESCC | 2.10e-12 | 1.63e-01 | 0.116 |
| 80067 | DCAF17 | P11T-E | Human | Esophagus | ESCC | 2.46e-02 | 1.14e-01 | 0.1426 |
| 80067 | DCAF17 | P12T-E | Human | Esophagus | ESCC | 5.05e-15 | 2.64e-01 | 0.1122 |
| 80067 | DCAF17 | P15T-E | Human | Esophagus | ESCC | 1.83e-09 | 1.91e-01 | 0.1149 |
| 80067 | DCAF17 | P16T-E | Human | Esophagus | ESCC | 1.32e-09 | 1.50e-01 | 0.1153 |
| 80067 | DCAF17 | P20T-E | Human | Esophagus | ESCC | 9.54e-15 | 2.68e-01 | 0.1124 |
| 80067 | DCAF17 | P21T-E | Human | Esophagus | ESCC | 2.73e-07 | 1.61e-01 | 0.1617 |
| 80067 | DCAF17 | P22T-E | Human | Esophagus | ESCC | 2.78e-09 | 1.23e-01 | 0.1236 |
| 80067 | DCAF17 | P23T-E | Human | Esophagus | ESCC | 1.66e-06 | 1.54e-01 | 0.108 |
| 80067 | DCAF17 | P24T-E | Human | Esophagus | ESCC | 3.99e-09 | 1.22e-01 | 0.1287 |
| 80067 | DCAF17 | P26T-E | Human | Esophagus | ESCC | 3.86e-13 | 1.87e-01 | 0.1276 |
| 80067 | DCAF17 | P27T-E | Human | Esophagus | ESCC | 2.46e-08 | 1.35e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCAF17 | SNV | Missense_Mutation | c.1515N>A | p.Met505Ile | p.M505I | Q5H9S7 | protein_coding | tolerated(0.08) | probably_damaging(0.961) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| DCAF17 | SNV | Missense_Mutation | c.265N>G | p.Pro89Ala | p.P89A | Q5H9S7 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DCAF17 | SNV | Missense_Mutation | c.1393N>C | p.Ser465Arg | p.S465R | Q5H9S7 | protein_coding | tolerated(0.3) | benign(0.099) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| DCAF17 | SNV | Missense_Mutation | c.131N>A | p.Ser44Asn | p.S44N | Q5H9S7 | protein_coding | tolerated(0.35) | benign(0.059) | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| DCAF17 | SNV | Missense_Mutation | c.961G>A | p.Ala321Thr | p.A321T | Q5H9S7 | protein_coding | deleterious(0.01) | benign(0.164) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DCAF17 | deletion | Frame_Shift_Del | novel | c.431delT | p.Ile144AsnfsTer12 | p.I144Nfs*12 | Q5H9S7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DCAF17 | SNV | Missense_Mutation | c.613N>C | p.Glu205Gln | p.E205Q | Q5H9S7 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| DCAF17 | SNV | Missense_Mutation | novel | c.1174N>T | p.Asn392Tyr | p.N392Y | Q5H9S7 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| DCAF17 | SNV | Missense_Mutation | c.265N>T | p.Pro89Ser | p.P89S | Q5H9S7 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DCAF17 | SNV | Missense_Mutation | c.455N>G | p.Phe152Cys | p.F152C | Q5H9S7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |